Dashboard
Manage Tickers

MRUS Merus N.V.

Nasdaq merus.nl


$ 94.98 $ 0.06 (0.06 %)    

Wednesday, 15-Oct-2025 16:01:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.39 $ -1.66 (-0.27 %)
DIA $ 462.75 $ -1.92 (-0.41 %)
SPY $ 665.10 $ -1.70 (-0.25 %)
TLT $ 90.69 $ -0.30 (-0.33 %)
GLD $ 387.52 $ 1.52 (0.39 %)
$ 94.83
$ 94.88
$ 94.81 x 100
$ 95.00 x 100
$ 94.82 - $ 94.96
$ 33.19 - $ 95.02
1,267,204
na
7.17B
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

merus-reports-interim-phase-2-results-for-petosemtamab-in-metastatic-colorectal-cancer
Merus Reports Interim Phase 2 Results for ...
10/14/2025 11:34:08

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific...

merus-reveals-petosemtamab-in-metastatic-colorectal-cancer-abstract-selected-for-plenary-session-oral-presentation-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-being-held-in-boston-massachusetts-on-october-22-26-2025
Merus Reveals Petosemtamab In Metastatic C...
10/13/2025 16:04:12

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, ...

leerink-partners-downgrades-merus-to-market-perform-raises-price-target-to-97
Leerink Partners Downgrades Merus to Marke...
10/06/2025 11:26:03

Leerink Partners analyst Andrew Berens downgrades Merus (NASDAQ:MRUS) from Outperform to Market Perform and raises the price...

this-maplebear-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday
This Maplebear Analyst Is No Longer Bullis...
09/30/2025 15:43:51

guggenheim-downgrades-merus-to-neutral-lowers-price-target-to-97
Guggenheim Downgrades Merus to Neutral, Lo...
09/30/2025 14:19:59

Guggenheim analyst Michael Schmitz downgrades Merus (NASDAQ:MRUS) from Buy to Neutral and lowers the price target from $109 ...

canaccord-genuity-downgrades-merus-to-hold-raises-price-target-to-97
Canaccord Genuity Downgrades Merus to Hold...
09/30/2025 13:38:14

Canaccord Genuity analyst John Newman downgrades Merus (NASDAQ:MRUS) from Buy to Hold and raises the price target from $67 t...

wells-fargo-downgrades-merus-to-equal-weight-raises-price-target-to-97
Wells Fargo Downgrades Merus to Equal-Weig...
09/30/2025 13:14:17

Wells Fargo analyst Eva Fortea Verdejo downgrades Merus (NASDAQ:MRUS) from Overweight to Equal-Weight and raises the price t...

ubs-downgrades-merus-to-neutral-raises-price-target-to-97
UBS Downgrades Merus to Neutral, Raises Pr...
09/30/2025 11:52:09

UBS analyst David Dai downgrades Merus (NASDAQ:MRUS) from Buy to Neutral and raises the price target from $72 to $97.

lifesci-capital-downgrades-merus-to-market-perform-announces-97-price-target
LifeSci Capital Downgrades Merus to Market...
09/30/2025 11:46:20

LifeSci Capital analyst Charles Zhu downgrades Merus (NASDAQ:MRUS) from Outperform to Market Perform and announces $97 price...

barclays-downgrades-merus-to-equal-weight-lowers-price-target-to-97
Barclays Downgrades Merus to Equal-Weight,...
09/30/2025 11:43:21

Barclays analyst Etzer Darout downgrades Merus (NASDAQ:MRUS) from Overweight to Equal-Weight and lowers the price target fro...

hc-wainwright--co-downgrades-merus-to-neutral-lowers-price-target-to-97
HC Wainwright & Co. Downgrades Merus to Ne...
09/30/2025 09:20:21

HC Wainwright & Co. analyst Andres Y. Maldonado downgrades Merus (NASDAQ:MRUS) from Buy to Neutral and lowers the price ...

truist-securities-downgrades-merus-to-hold-raises-price-target-to-97
Truist Securities Downgrades Merus to Hold...
09/29/2025 18:25:16

Truist Securities analyst Asthika Goonewardene downgrades Merus (NASDAQ: MRUS) from Buy to Hold and raises the price target ...

crude-oil-falls-sharply-carnival-posts-upbeat-earnings
Crude Oil Falls Sharply; Carnival Posts Up...
09/29/2025 17:14:55

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded do...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
09/29/2025 17:06:50

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands...

tilray-brands-sndl-innoviz-technologies-pony-ai--and-other-big-stocks-moving-higher-on-monday
Tilray Brands, SNDL, Innoviz Technologies,...
09/29/2025 15:54:19

U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Monday. Shares of Tilray Brands, Inc. (NAS...

genmab-makes-8-billion-bet-on-merus-with-potential-cancer-breakthrough
Genmab Makes $8 Billion Bet On Merus With ...
09/29/2025 14:15:02

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V.

needham-downgrades-merus-to-hold-maintains-price-target-to-96
Needham Downgrades Merus to Hold, Maintain...
09/29/2025 14:07:07

Needham analyst Ami Fadia downgrades Merus (NASDAQ: MRUS) from Buy to Hold and maintains the price target from $96 to $96.

expert-outlook-merus-through-the-eyes-of-4-analysts
Expert Outlook: Merus Through The Eyes Of ...
09/29/2025 13:09:45

In the preceding three months, 4 analysts have released ratings for Merus (NASDAQ: MRUS), presenting a wide array of perspectiv...

citigroup-downgrades-merus-to-neutral-lowers-price-target-to-97
Citigroup Downgrades Merus to Neutral, Low...
09/29/2025 12:28:36

Citigroup analyst Yigal Nochomovitz downgrades Merus (NASDAQ: MRUS) from Buy to Neutral and lowers the price target from $10...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
09/29/2025 12:09:33

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION